824 related articles for article (PubMed ID: 30819375)
41. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study.
Rutten JH; Mattace-Raso FU; Steyerberg EW; Lindemans J; Hofman A; Wieberdink RG; Breteler MM; Witteman JC; van den Meiracker AH
Hypertension; 2010 Mar; 55(3):785-91. PubMed ID: 20083731
[TBL] [Abstract][Full Text] [Related]
42. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Borné Y; Persson M; Melander O; Smith JG; Engström G
Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
[TBL] [Abstract][Full Text] [Related]
43. Gender Difference in the Prognostic Value of N-Terminal Pro-B Type Natriuretic Peptide in Patients With Heart Failure - A Report From the Korean Heart Failure Registry (KorHF).
Kim HL; Kim MA; Choi DJ; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Shin MS; Seong IW; Ahn Y; Kang SM; Kim YJ; Kim HS; Chae SC; Oh BH; Lee MM; Ryu KH;
Circ J; 2017 Aug; 81(9):1329-1336. PubMed ID: 28442636
[TBL] [Abstract][Full Text] [Related]
44. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease.
Ndrepepa G; Kastrati A; Braun S; Mehilli J; Niemöller K; von Beckerath N; von Beckerath O; Vogt W; Schömig A
Am J Med; 2006 Apr; 119(4):355.e1-8. PubMed ID: 16564781
[TBL] [Abstract][Full Text] [Related]
45. A comparison of risk factors as predictors of cardiovascular and non-cardiovascular mortality in the elderly people--relevance of N-terminal pro-B-type natriuretic peptide and low systolic blood pressure.
Muscari A; Bianchi G; Forti P; Giansante C; Giovagnoli M; Magalotti D; Pandolfi P; Perlangeli V; Zorzi V; Zoli M;
Int J Clin Pract; 2013 Nov; 67(11):1182-91. PubMed ID: 24165431
[TBL] [Abstract][Full Text] [Related]
46. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF).
McGrady M; Reid CM; Shiel L; Wolfe R; Boffa U; Liew D; Campbell DJ; Prior D; Stewart S; Krum H
Int J Cardiol; 2013 Oct; 169(2):133-8. PubMed ID: 24080362
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death.
Schrage B; Geelhoed B; Niiranen TJ; Gianfagna F; Vishram-Nielsen JKK; Costanzo S; Söderberg S; Ojeda FM; Vartiainen E; Donati MB; Magnussen C; Di Castelnuovo A; Camen S; Kontto J; Koenig W; Blankenberg S; de Gaetano G; Linneberg A; Jørgensen T; Zeller T; Kuulasmaa K; Tunstall-Pedoe H; Hughes M; Iacoviello L; Salomaa V; Schnabel RB
J Am Heart Assoc; 2020 May; 9(9):e015218. PubMed ID: 32351154
[TBL] [Abstract][Full Text] [Related]
48. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
[TBL] [Abstract][Full Text] [Related]
49. Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project.
Rehm M; Rothenbacher D; Iacoviello L; Costanzo S; Tunstall-Pedoe H; Fitton CA; Söderberg S; Hultdin J; Salomaa V; Jousilahti P; Palosaari T; Kuulasmaa K; Waldeyer C; Schnabel RB; Zeller T; Blankenberg S; Koenig W;
ESC Heart Fail; 2022 Feb; 9(1):57-65. PubMed ID: 34825788
[TBL] [Abstract][Full Text] [Related]
50. Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men.
Dorans KS; Mostofsky E; Levitan EB; Håkansson N; Wolk A; Mittleman MA
Circ Heart Fail; 2015 May; 8(3):422-7. PubMed ID: 25872788
[TBL] [Abstract][Full Text] [Related]
51. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
[TBL] [Abstract][Full Text] [Related]
52. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP
JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209
[TBL] [Abstract][Full Text] [Related]
53. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
[TBL] [Abstract][Full Text] [Related]
54. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.
Ndumele CE; Matsushita K; Sang Y; Lazo M; Agarwal SK; Nambi V; Deswal A; Blumenthal RS; Ballantyne CM; Coresh J; Selvin E
Circulation; 2016 Feb; 133(7):631-8. PubMed ID: 26746175
[TBL] [Abstract][Full Text] [Related]
55. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
Berntsson J; Zia E; Borné Y; Melander O; Hedblad B; Engström G
Cerebrovasc Dis; 2014; 37(6):444-50. PubMed ID: 25060145
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
[TBL] [Abstract][Full Text] [Related]
57. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
[TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
[TBL] [Abstract][Full Text] [Related]
59. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
60. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
